From the Journals: Editors’ Picks
As a regular feature on this blog, we spotlight 10 “must read” articles selected by our editors from each...
As a regular feature on this blog, we spotlight 10 “must read” articles selected by our editors from each...
recent data suggest that there is another potential contender for a biomarker-based FDA approval: a targeted therapeutic called larotrectinib...
Pediatric cancer, while rare, is the leading cause of death by disease among children past infancy in the developed world. The World Health Organization notes...
Experts identify opportunities and challenges facing cancer researchers in 2017.
The U.S. Preventive Services Task Force (USPSTF) released draft recommendations April 11 suggesting that doctors inform men ages 55...
Levi Garraway, MD, PhD, co-chair of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston Nov....
Expanding clinical trial eligibility requirements can help increase participation and more accurately show how treatments work in a real-world...
Cancer patient advocates take on many roles in their communities. They may go out to churches to promote the...
When faced with a cancer diagnosis, patients often find themselves asking, “How long will I live? Which treatments will...
Over the past decade, immune checkpoint inhibitors have transformed cancer care for a variety of tumor types. This form of immunotherapy can lead to long-lasting...
Earlier this week, the U.S. Food and Drug Administration (FDA) approved the molecularly targeted therapeutic niraparib (Zejula) for the...
For the month of August, the editors of the nine AACR journals have chosen to highlight results from two clinical...
Most breast cancers express the estrogen and/or progesterone hormone receptors, which fuel tumor growth upon engagement with their respective...
Welcome to Cancer Research Catalyst, the official blog of the American Association for Cancer Research (AACR). With this blog,...
Guest Post by Kent Osborne, MD Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine;...
May is National Cancer Research Month, during which the American Association for Cancer Research partners with advocacy groups, cancer...
After a hiatus caused by the pandemic, Party with a Purpose, a cause-driven gala in Philadelphia that supports cancer...
Based on estimates from the National Cancer Institute, in 2023, more than 110,000 cases of gynecologic cancers are expected...
The Global Scholar Alumni Committee reflects on their progress after the first year in helping the careers of young...
The American Association for Cancer Research (AACR) is proud to offer Global Scholar-in-Training Awards (GSITA) to support the career...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...
In addition to the robust scientific program at this year’s AACR Annual Meeting in Washington, D.C., a number of...
For the second consecutive year, this year’s AACR Annual Meeting will take place in a virtual format. While we...
The new year brings a new chapter in the holy book of cancer biology with the publication in the...
China, a nation of 1.3 billion people, is facing an ongoing cancer epidemic, with more than 3 million people...
The COVID-19 pandemic continues to impact the United States and other parts of the world. To date, 13 million cases have been...
A study published recently in the AACR’s journal Cancer Discovery addresses the burgeoning question of the utility of high-throughput...
Last week, the U.S. Food and Drug Administration (FDA) approved the use of cobimetinib (Cotellic) in combination with vemurafenib...
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more...
The 2020 death of actor Chadwick Boseman shocked the public, sparking grief in those who revered his portrayal of...